PS
FDMT icon

Planning Strategies’s 4D Molecular Therapeutics FDMT Stock Holding History

Planning Strategies’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.68K Buy
+502
New +$4.89K ﹤0.01% 385

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Planning Strategies's FDMT Position: Q2 2026 in Review

Planning Strategies opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 502 shares worth $6.68K. The stake represents ﹤0.01% of the portfolio and ranks #385 among its holdings.

149 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Planning Strategies held 502 shares of 4D Molecular Therapeutics worth $6.68K as of Q2 2026.
  • 4D Molecular Therapeutics was a new Planning Strategies position in Q2 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Planning Strategies's portfolio in Q2 2026, its #385 holding.
  • 149 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Planning Strategies's 13F filing for Q2 2026, filed 27 Jul 2026.